PT  - JOURNAL ARTICLE
AU  - Yuan, Victoria
AU  - Vukadinovic, Milos
AU  - Kwan, Alan C.
AU  - Rader, Florian
AU  - Li, Debiao
AU  - Ouyang, David
TI  - Clinical and genetic associations of asymmetric apical and septal left ventricular hypertrophy
AID  - 10.1101/2023.10.03.23296510
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.10.03.23296510
4099  - http://medrxiv.org/content/early/2023/10/05/2023.10.03.23296510.short
4100  - http://medrxiv.org/content/early/2023/10/05/2023.10.03.23296510.full
AB  - Increased left ventricular mass has been associated with adverse cardiovascular outcomes including incident cardiomyopathy and atrial fibrillation. Such associations have been studied in relation to total left ventricular hypertrophy, while the regional distribution of myocardial hypertrophy is extremely variable and the clinical significant and genetic associations of such variability requires further study. Here, we use deep learning derived phenotypes of disproportionate patterns of hypertrophy, such as apical hypertrophy and septal hypertrophy, to study genome-wide and clinical associations in addition to and independent from total left ventricular mass within 35,268 UK Biobank participants. Adjusting for total left ventricular mass, apical hypertrophy is associated with elevated risk for cardiomyopathy and atrial fibrillation, and the risk for cardiomyopathy was increased for subjects with increased apical or septal mass even in the absence of global hypertrophy. We identified seventeen genome-wide associations for left ventricular mass, three unique associations with increased apical mass, and three additional unique associations with increased septal mass. Further studies are needed in multi-ethnic cohorts.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The source data were publicly available prior to the initiation of this study. UK Biobank data is available with an approved study protocol (https://www.ukbiobank.ac.uk/).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesUK Biobank data is available with an approved study protocol. https://www.ukbiobank.ac.uk/